scholarly journals Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor

2018 ◽  
Vol 12 (3) ◽  
pp. 629-632 ◽  
Author(s):  
Hassan Al Moussawi ◽  
Abhishek D. Polavarapu ◽  
Divya Asti ◽  
Zainab Awada ◽  
Stephen  Mulrooney
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Cirrhotic Patient ◽  
Cell Disease ◽  
Hcv Treatment ◽  
Direct Acting Antiviral ◽  
Thalassemia Minor ◽  
Direct Acting

Around 8% of patients diagnosed with sickle cell disease (SCD) are hepatitis C virus (HCV) carriers. Previously, HCV treatment was seldom considered in SCD patients, as the ribavirin-induced hemolysis and interferon-induced cytopenias could lead to more profound anemia. Nowadays, several oral direct-acting antiviral drugs have been developed and approved by the FDA for hepatitis C treatment. While direct-acting antivirals mitigate many of these risks, their safety and efficacy in SCD patients remains insufficiently explored. Here, we report on successfully treating HCV with ledipasvir/sofosbuvir in a compensated cirrhotic patient with SCD and thalassemia minor.

scholarly journals Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy

2020 ◽  
Vol 11 ◽  
Author(s):  
Nadia A. Nabulsi ◽  
Michelle T. Martin ◽  
Lisa K. Sharp ◽  
David E. Koren ◽  
Robyn Teply ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Failure ◽  
Antiviral Therapy ◽  
Characteristic Curve ◽  
Predictive Ability ◽  
Predictive Performance ◽  
Hcv Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

Introduction: Hepatitis C virus (HCV), the leading cause of advanced liver disease, has enormous economic burden. Identification of patients at risk of treatment failure could lead to interventions that improve cure rates.Objectives: Our goal was to develop and evaluate a prediction model for HCV treatment failure.Methods: We analyzed HCV patients initiating direct-acting antiviral therapy at four United States institutions. Treatment failure was determined by lack of sustained virologic response (SVR) 12 weeks after treatment completion. From 20 patient-level variables collected before treatment initiation, we identified a subset associated with treatment failure in bivariate analyses. In a derivation set, separate predictive models were developed from 100 bootstrap samples using logistic regression. From the 100 models, variables were ranked by frequency of selection as predictors to create four final candidate models, using cutoffs of ≥80%, ≥50%, ≥40%, and all variables. In a validation set, predictive performance was compared across models using area under the receiver operating characteristic curve.Results: In 1,253 HCV patients, overall SVR rate was 86.1% (95% CI = 84.1%, 88.0%). The AUCs of the four final candidate models were: ≥80% = 0.576; ≥50% = 0.605; ≥40% = 0.684; all = 0.681. The best performing model (≥40%) had significantly better predictive ability than the ≥50% (p = 0.03) and ≥80% models (p = 0.02). Strongest predictors of treatment failure were older age, history of hepatocellular carcinoma, and private (vs. government) insurance.Conclusion: This study highlighted baseline factors associated with HCV treatment failure. Treatment failure prediction may facilitate development of data-driven clinical tools to identify patients who would benefit from interventions to improve SVR rates.

Ledipasvir/Sofosbuvir for Hepatitis C Cirrhosis With Sickle Cell Disease and Thalassemia Minor

2017 ◽  
Vol 112 ◽  
pp. S1262-S1263
Author(s):  
Abhishek D. Polavarapu ◽  
Hassan Al Moussawi ◽  
Mayurathan Kesavan ◽  
Stephen Mulrooney
Keyword(s):  
Hepatitis C ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Cell Disease ◽  
Thalassemia Minor

scholarly journals Analysis of hepatitis C virus infection among sickle cell anemia patients by an antigen-antibody combination assay

2011 ◽  
Vol 2 (1) ◽  
pp. 26
Author(s):  
Obeid E. Obeid ◽  
Alhusain J. Alzahrani
Keyword(s):  
Saudi Arabia ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Viral Genome ◽  
Core Antigen ◽  
Cell Disease ◽  
Antigen Antibody

Hepatitis C virus (HCV) has a major impact on public health. In spite of the progress made in the prevention of transfusion-transmitted infections over the last years, these still occur, especially in multi-transfused patients such as sickle cell anemia patients. Sickle cell disease (SCD) is highly prevalent in Eastern Saudi Arabia. Little is known about the prevalence of HCV in Saudi sickle cell disease patients. The present study aimed to assess HCV and HBV antigens, antibodies and viral genome among sickle cell anemia patients in a tertiary hospital in Eastern Saudi Arabia. Methods used included measurement of HCV antigen and antibodies using the novel HCV antigen/antibody combination assay, assessment of HCV core antigen and measurement of viral genome using standard commercial kits. Of the 138 sickle cell disease samples tested, 5 (3.6%) samples gave positive results. Their hemoglobin ranged between 7.8 and 10.1 g/dL, their erythrocyte count ranged between 3.1¥106 and 3.9¥106. Out of these 5 samples, 4 were also positive by the HCV Core Ag assay and by the HCV RNA PCR test (80%). None of the control group was positive. Seven patients were positive for HBs antibodies. One sample was positive for HBsAg, and this indicates chronic carrier state. Improving the testing for blood-borne infections such as HCV and HBV will result in better control of these infections in sickle cell disease patients which will inevitably lead to lower mortality and morbidity in this group of patients.

Hepatitis C Virus Infection in Maintenance Hemodialysis Patients: Recommendations for Diagnostics and Treatment

2016 ◽  
Vol 39 (12) ◽  
pp. 590-595 ◽  
Author(s):  
Pavlina Dzekova-Vidimliski ◽  
Aleksandar Sikole
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Treatment ◽  
Antiviral Agents ◽  
Hemodialysis Patients ◽  
Maintenance Hemodialysis ◽  
Direct Acting Antivirals ◽  
Hcv Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

Hepatitis C virus (HCV) infection is highly prevalent among patients treated with maintenance hemodialysis and is an important cause of morbidity and mortality. It is necessary to determine the HCV genotype and the viral load to monitor the clinical and laboratory features and to establish an optimal antiviral treatment strategy. Antiviral treatments are presented with a standard interferon-based regimen and new direct-acting antiviral agents. The advent of direct-acting antivirals has improved the efficacy and safety of HCV treatment for most patients, even in difficult-to-treat populations such as patients on hemodialysis. HCV treatment with direct-acting antivirals in hemodialysis patients is highly effective, with viral eradication rates similar to those seen in patients without chronic kidney disease and with acceptable adverse event profiles.

Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C

2019 ◽  
Vol 14 (11) ◽  
pp. 715-727
Author(s):  
Kelli Wuerth ◽  
Tianna Magel ◽  
Brian Conway
Keyword(s):  
Clinical Trials ◽  
Chronic Hepatitis ◽  
Life Cycle ◽  
Clinical Practice ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hcv Treatment ◽  
Real World Data ◽  
Direct Acting Antiviral ◽  
Direct Acting

Advances in hepatitis C virus (HCV) treatment led to the development of highly effective all oral direct acting antiviral regimens. The combination of sofosbuvir and velpatasvir (SOF/VEL), two agents acting synergistically at different stages in the viral life cycle, has been evaluated in a broad range of clinical trials supporting its efficacy in complex and diverse patient populations. Following regulatory approval in 2016, SOF/VEL has been widely used as a safe, effective pangenotypic regimen in clinical practice. In this review, we will discuss the current preclinical, clinical and real-world data on SOF/VEL.

scholarly journals Superimposed Hepatitis C Virus in Sickle Cell Disease Pregnant Woman

2018 ◽  
Vol 7 (1) ◽  
pp. 158
Author(s):  
AzarDanesh Shahraki ◽  
Azam Zafarbakhsh ◽  
AmirrezaFarhadian Dehkordi
Keyword(s):  
Hepatitis C Virus ◽  
Pregnant Woman ◽  
Hepatitis C ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Cell Disease

Cure of chronic hepatitis C virus infection in an HIV-coinfected patient with multiple comorbidities and drug interaction challenges

2018 ◽  
Vol 29 (9) ◽  
pp. 933-936
Author(s):  
Hortensia Álvarez ◽  
Ana Mariño ◽  
Nieves Valcarce ◽  
Saye Khoo ◽  
Sanjay Bhagani ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Amiodarone Therapy ◽  
Hcv Treatment ◽  
Direct Acting Antiviral ◽  
Hiv Coinfection ◽  
Coinfected Patient ◽  
Direct Acting ◽  
End Stage

Curing hepatitis C virus (HCV) infection in patients harbouring multiple severe comorbidities is a medical challenge. Evidence-based data are lacking regarding HCV treatment with direct-acting antiviral regimens in particular populations of HCV/HIV-coinfected patients with cirrhosis and chronic kidney disease on haemodialysis. Here, we present the HCV treatment challenges facing a patient with HIV coinfection, prior failure of both HIV-1 and HCV therapy, cirrhosis, end-stage renal failure on haemodialysis, as well as management of drug–drug interactions, especially given the need to receive long-term amiodarone therapy.

Sign in / Sign up

Export Citation Format

Share Document